Dr. Sven K. Weber Appointed CEO of BRAIN Biotech AG as Adriaan Moelker Retires

Dr. Sven K. Weber will succeed Adriaan Moelker as CEO of BRAIN Biotech AG effective October 1, 2026, bringing expertise in industrial enzymes to accelerate growth and profitability.

LA Metrowire Staff
Technology
Dr. Sven K. Weber Appointed CEO of BRAIN Biotech AG as Adriaan Moelker Retires

The Supervisory Board of BRAIN Biotech AG has appointed Dr. Sven K. Weber as the new CEO, effective October 1, 2026, succeeding Adriaan Moelker, who will retire as scheduled at the end of his contract term. Moelker will continue as a senior advisor until January 2027.

Dr. Weber, 44, joins from BASF Group, where he served as Vice President responsible for the global enzyme business. He drove innovation-led profitable growth and significantly increased revenue and earnings. Previously, he held roles at Chemetall GmbH and hte GmbH, and began his career at Merck Group. He holds a diploma and doctorate in chemistry from the University of Heidelberg and completed an executive program at SGMI Management Institute in St. Gallen.

Dr. Michael Majerus, Chairman of the Supervisory Board, thanked Moelker for repositioning BRAIN as an integrated manufacturing company in enzymes and successfully monetizing projects from the BRAINBioIncubator. He expressed confidence in Dr. Weber's ability to continue the strategic direction, tap into growth potential, and accelerate operational implementation.

Dr. Weber stated his intention to build on BRAIN's strong technological foundation and scientific expertise to accelerate growth, strengthen profitability, and bring innovative products to market more quickly. His goal is to develop BRAIN into a leading provider of specialty enzymes in selected application areas and leverage the BRAINBioIncubator for additional growth.

The BRAIN Biotech Group specializes in researching, developing, and producing specialty enzymes for food and life sciences. It also develops microbial production strains and scalable bioprocesses. With operations in the UK, continental Europe, and the US, the group generated €49.6 million in revenue in the 2024/25 fiscal year with around 280 employees. More information is available at www.brain-biotech-group.com.

This leadership change signals a continued focus on innovation and growth in the enzyme sector, leveraging Dr. Weber's experience to enhance profitability and market position.

Blockchain Registration

QR Code for Blockchain Registration